Adarx Pharmaceuticals Inc. is seeking to raise as much as $371.9 million in a US initial public offering, according to Bloomberg.
The late-stage gene therapy developer disclosed the fundraising target in its IPO filing.
Article
Adarx Pharma Targets $371.9 Million in US IPO
--・
Disclaimer: Includes third-party opinions. No advice. Binance AI may be used without guarantee. See T&Cs.